Genzyme Escapes Investor Class Action Over Stock Plunge
The First Circuit refused Thursday to revive a consolidated class action accusing Genzyme Corp. of misleading the U.S. Food and Drug Administration over manufacturing plant problems and selling its securities at...To view the full article, register now.
Already a subscriber? Click here to view full article